Halma plc HLMA.L
Composite 51/100; the shares have moved about 38% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Valuation ranks 19/100 — a strong mark against it.
Growth ranks 67/100 — a moderate point in its favour. Balance-sheet strength ranks 67/100 — a moderate point in its favour. Quality ranks 66/100 — a moderate point in its favour.
Valuation ranks 19/100 — a strong mark against it. Momentum ranks 31/100 — a moderate mark against it. Income ranks 40/100 — a slight mark against it.
What the company does Halma plc designs and sells safety, environmental, and healthcare technology solutions across global markets. Its segments include Safety (fire, public, worker, and infrastructure protection), Environmental & Analysis (water treatment and monitoring), and Healthcare (diagnostics and therapeutic solutions).
Key financials Halma posts strong profitability with ROE 18.3%, ROA 9.5%, and ROCE 26.6%. Margins are healthy: gross 50.0%, operating 20.6%, net 14.4%. Revenue and EPS growth are 14.6% and 16.0%, respectively, with a Piotroski F-Score of 7/9 and Altman Z of 8.05.
Stock health The balance sheet is solid: debt/equity 0.42, net debt/EBITDA 1.24, interest coverage 12.27, and current ratio 2.14. Momentum is weak with 3m -22.25%, 6m -4.42%, and RSI(14) at 26.00, indicating oversold conditions.
Price vs fair value The stock trades at a PREMIUM of 31.40% versus our fair-value estimate and at a discount of 28.64% versus the analyst 12-month target. - Valuation percentile of 24.1/100 signals rich pricing (Valuation 24.1) - Forward P/E of 27.55 and PEG of 0.90 reflect high growth expectations (Fwd P/E 27.55, Forward PEG 0.90) - 12-month return of 5.32% lags peers despite strong fundamentals (12m 5.32%)
Looking forward Analysts expect continued growth, with a 12-month target of 4386.47 implying 28.64% upside. Execution in high-margin segments and margin expansion will be key to justifying current valuations.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-03, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.